Back to results
US 11,590,138 B2Granted
Topical treatment of vitiligo by a jak inhibitor
AssigneeIncyte Corporation
InventorsKathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Claims21
A method of treating vitiligo in an affected area of a patient comprising:
- topically administering to the affected skin area of the patient in need thereof a pharmaceutical composition comprising 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day and the vitiligo is nonsegmental vitiligo,
- wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient, and
- wherein the method does not comprise administering phototherapy.
A method of treating vitiligo in an affected area of a patient comprising:
- topically administering to the affected skin area of the patient in need thereof a pharmaceutical composition comprising 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day and the vitiligo is nonsegmental vitiligo,
- wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient,
- wherein the method does not comprise administering phototherapy, and
- wherein topically administering of the pharmaceutical composition is continued to achieve a 50% or greater improvement in Vitiligo Area Scoring Index in the affected skin area that is at least one of the lower extremities, the trunk, and the feet after 52 weeks.
1 more element
Dependencies are inferred from the claim text.